Core Viewpoint - 基石药业-B's stock rose over 5% following the approval of a new indication for Shugli monoclonal antibody by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating specific adult patients with inoperable stage III non-small cell lung cancer (NSCLC) [1] Group 1 - 基石药业-B's stock increased by 5.12%, reaching HKD 6.36, with a trading volume of HKD 23.93 million [1] - The MHRA approved Shugli monoclonal antibody for use in adult patients with NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - This approval follows the European Commission's approval, marking the second indication approval for Shugli monoclonal antibody in the UK [1] Group 2 - Shugli monoclonal antibody has established four commercialization partnerships across Europe, the Middle East, Africa, and Latin America, covering over 60 countries and regions [1] - The company is actively advancing its commercialization efforts overseas [1]
港股异动 | 基石药业-B(02616)涨超5% 舒格利单抗III期非小细胞肺癌新适应症获英国MHRA批准